Saphris FDA Approval History
FDA Approved: Yes (First approved August 13, 2009)
Brand name: Saphris
Generic name: asenapine
Dosage form: Sublingual Tablets
Company: AbbVie Inc.
Treatment for: Schizophrenia, Bipolar Disorder
Saphris (asenapine) is an atypical antipsychotic for the treatment of schizophrenia and acute mania or mixed episodes associated with bipolar I disorder.
Development timeline for Saphris
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.